CULLINAN THERAPEUTICS, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 19.22 USD | +1.77% |
|
+6.64% | +89.01% |
Presenter SpeechUnknown Analyst (Analysts)Good morning. Thank you for attending the conference...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Cullinan Therapeutics, Inc., formerly Cullinan Oncology, Inc., is a biopharmaceutical company focused on developing modality-agnostic targeted therapies. It has a portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its pipeline includes CLN-619, CLN-978, Zipalertinib (CLN-081/TAS6417), CLN-049, CLN-418, and CLN-617. Its lead unpartnered program, CLN-619, is a humanized lgG1 monoclonal antibody (mAb) that binds to the stress induced ligands MICA and MICB (MICA/B), which are expressed on a variety of solid tumors and hematologic malignancies. CLN-978 is a novel, highly potent, half-life extended CD19xCD3 bispecific T cell engager construct. CLN-081/TAS6417 is a novel, orally available, covalent inhibitor of mutant epidermal growth factor receptor (EGFR). CLN-049 is a FLT3xCD3 T cell engaging bispecific antibody. CLN-418 is a B7H4 x 4-1BB bispecific immune activator.
Calendar
2024-05-08
- Q1 2024 Earnings Release (Projected)
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
18.89
USD
Average target price
28.71
USD
Spread / Average Target
+52.01%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +89.01% | 814M | |
| +1.02% | 43.84B | |
| +6.46% | 41.68B | |
| +45.26% | 41.25B | |
| -11.96% | 27.04B | |
| +6.58% | 25.53B | |
| -24.50% | 18.18B | |
| -3.92% | 12.29B | |
| +25.94% | 12.29B | |
| +7.09% | 11.15B |
- Stock Market
- Equities
- CGEM Stock
- News Cullinan Therapeutics, Inc.
- Transcript : Cullinan Oncology, Inc. Presents at Credit Suisse 31st Annual Healthcare Conference, Nov-07-2022 through Nov-10-2022
